Study of Protection And Repair of Endothelial-glycocalyx in Sepsis (SPARES)
Phase 2 – studying effectiveness and dosage
Conditions:
Sepsis
Sponsor: Beth Israel Deaconess Medical Center
trial.available_in:
БГ
Overview
Sepsis damages the blood vessel lining and its protective "glycocalyx," contributing to organ failure and death. This pilot, randomized, blinded study will test whether giving fresh frozen plasma (FFP)-either as intermittent boluses or as a continuous infusion-protects or repairs the glycocalyx compared with look-alike placebo fluid (lactated Ringer's with multivitamins), and whether this leads to better clinical outcomes. We will measure blood and urine biomarkers of glycocalyx injury and track organ support needs, ICU/hospital-free days, and survival through 28-90 days.
Description
Multicenter, blinded, placebo-controlled randomized pilot trial comparing: (1) Fresh Frozen Plasma bolus regimen; (2) FFP continuous infusion; and (3) placebo (Lactated Ringers with multivitamins, administered as bolus or semi-continuous to maintain blinding). Primary biologic readout is change in syndecan-1 (glycocalyx degradation) with additional endothelial activation and inflammation markers; key clinical endpoints include mortality and organ failure-free days. Target enrollment is 45 adults with sepsis (Sequential Organ Failure Assessment (SOFA) ≥2) within Intensive Care Unit or Emergency Department settings.
Who can participate
Inclusion Criteria:
* Age ≥18 years
* Confirmed or suspected infection (pathogen detected or antimicrobial administered)
* SOFA score ≥2
* ICU patient or ED patient with anticipated ICU admission
Exclusion Criteria:
* Unable to randomize within 24h of meeting inclusion criteria
* Current hospitalization \>2 days
* Decision to withhold life-sustaining treatment (exception for DNR only)
* Moribund; not expected to survive 24h
* Life expectancy \<28 days from non-sepsis condition
* Any condition where participation isn't in the patient's best interest or limits assessments
* Prisoner
* Pregnancy
* Concurrent interventional trial with overlapping treatments/outcomes
* Inability to obtain patient/LAR consent
* History of Transfusion Related Acute Lung Injury (TRALI) or Transfusion Associated Circulatory Overload (TACO)
* End Stage Renal Disease
* Chronic tracheostomy with ventilator use